English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Single-nucleotide polymorphisms (SNPs) of  TP53  (codon 72, rs1042522) and  MDM2  promoter (SNP 309, rs2279744) have been associated with risk for various human cancers. However, studies analyzing these polymorphisms in pancreatic ductal adenocarcinoma (PDAC) are lacking. We investigated  TP53  codon 72 and  MDM2  SNP 309 polymorphisms in 32 patients with PDAC, 16 patients with chronic pancreatitis (CP), and 32 normal controls, using formalin-fixed paraffin-embedded tissue. We also examined  TP53  and  MDM2  protein immunohistochemistry (IHC) to assess the involvement of these differences in malignant transformation and disease progression.  TP53  Pro/Pro genotype was significantly more frequent in PDAC patients than in controls (65.6  vs . 15.6%,  p  < 0.001) and no significant difference was found between CP patients (37.5%) and controls. In  MDM2  SNP 309, there were no significant differences among the three groups. Based on the Kaplan-Meier analysis, overall survival was significantly shorter in  MDM2  G/G genotypes compared with other genotypes (G/T and T/T) (359  vs . 911 days,  p  = 0.016) whereas no significant differences in  TP53  genotypes were observed (638  vs . 752 days,  p  = 0.471). Although  TP53  IHC was frequent in PDAC patients (53.1%),  TP53  and  MDM2  protein expression was not correlated with polymorphisms. Our study demonstrated  TP53  codon 72 polymorphism is potentially a genetic predisposing factor while  MDM2  SNP 309 polymorphism might be useful in predicting survival outcome.

Impact of TP53 Codon 72 and MDM2 SNP 309 Polymorphisms in Pancreatic Ductal Adenocarcinoma